SEC Company Response from AVADEL PHARMACEUTICALS PLC (AVDL) (CIK 0001012477) — Feb 13, 2020
AVADEL PHARMACEUTICALS PLC (AVDL) (CIK 0001012477)
Date: Feb. 13, 2020 · CIK: 0001012477 · Accession: 0001104659-20-020407
AI Filing Summary & Sentiment
File numbers found in text: 333-236258
Letter
Avadel Pharmaceuticals plc
10 Earlsfort Terrace
Dublin 2, Ireland
D02 T380
February 13, 2020
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Avadel Pharmaceuticals plc: Registration Statement on Form S-3 filed February 5, 2020 (File No. 333-236258)
Ladies and Gentlemen:
Avadel Pharmaceuticals plc (the “Company”) hereby respectfully requests withdrawal of its acceleration request filed on February 13, 2020 relating to the above-referenced registration statement (the “Registration Statement”). The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this request, please contact Robert E. Puopolo of Goodwin Procter LLP at (617) 570-1393.
Sincerely,
Avadel Pharmaceuticals plc
Show Raw Text
CORRESP
1
filename1.htm
Avadel Pharmaceuticals plc
10 Earlsfort Terrace
Dublin 2, Ireland
D02 T380
February 13, 2020
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Avadel Pharmaceuticals plc: Registration Statement
on Form S-3 filed February 5, 2020 (File No. 333-236258)
Ladies and Gentlemen:
Avadel Pharmaceuticals plc (the “Company”)
hereby respectfully requests withdrawal of its acceleration request filed on February 13, 2020 relating to the above-referenced
registration statement (the “Registration Statement”). The Company is no longer requesting that such Registration
Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this
request, please contact Robert E. Puopolo of Goodwin Procter LLP at (617) 570-1393.
Sincerely,
Avadel Pharmaceuticals plc
/s/ Gregory J. Divis
Gregory J. Divis
Chief Executive Officer and Principal Executive Officer
cc: Thomas McHugh, Avadel Pharmaceuticals plc
Phillandas Thompson, Avadel
Pharmaceuticals plc
Robert E. Puopolo, Esq., Goodwin Procter
LLP